Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a debilitating condition where excess collagen
deposition occurs in the extracellular matrix. At first sight, it is expected that the level of …
deposition occurs in the extracellular matrix. At first sight, it is expected that the level of …
Nutrition in patients with idiopathic pulmonary fibrosis: critical issues analysis and future research directions
P Faverio, M Bocchino, A Caminati, A Fumagalli… - Nutrients, 2020 - mdpi.com
In idiopathic pulmonary fibrosis (IPF), several factors may have a negative impact on the
nutritional status, including an increased respiratory muscles load, release of inflammation …
nutritional status, including an increased respiratory muscles load, release of inflammation …
Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo …
SB Andugulapati, K Gourishetti, SK Tirunavalli… - Phytomedicine, 2020 - Elsevier
Abstract Background: Idiopathic Pulmonary Fibrosis (IPF) is a progressive inflammatory
disorder driven by a fibrotic cascade of events such as epithelial to mesenchymal transition …
disorder driven by a fibrotic cascade of events such as epithelial to mesenchymal transition …
Geriatric Nutritional Risk Index is a predictor of tolerability of antifibrotic therapy and mortality risk in patients with idiopathic pulmonary fibrosis
Y Mochizuka, Y Suzuki, M Kono, H Hasegawa… - …, 2023 - Wiley Online Library
Abstract Background and Objective Idiopathic pulmonary fibrosis (IPF) is characterized by
progressive lung fibrosis of unknown aetiology. Epidemiological studies have suggested …
progressive lung fibrosis of unknown aetiology. Epidemiological studies have suggested …
Post hoc analysis of clinical outcomes in placebo-and pirfenidone-treated patients with IPF stratified by BMI and weight loss
S Jouneau, B Crestani, R Thibault, M Lederlin… - Respiration, 2022 - karger.com
Background: Weight loss is frequently reported in patients with idiopathic pulmonary fibrosis
(IPF) and may be associated with worse outcomes in these patients. Objective: The aim of …
(IPF) and may be associated with worse outcomes in these patients. Objective: The aim of …
A systematic review of the prognostic significance of the body mass index in idiopathic pulmonary fibrosis
The identification of novel prognostic biomarkers might enhance individualized
management strategies in patients with idiopathic pulmonary fibrosis (IPF). Although several …
management strategies in patients with idiopathic pulmonary fibrosis (IPF). Although several …
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
T Yoshikawa, M Otsuka, H Chiba, K Ikeda, Y Mori… - BMC pulmonary …, 2020 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease
with poor prognosis. Pirfenidone and nintedanib are anti-fibrotic drugs used for patients with …
with poor prognosis. Pirfenidone and nintedanib are anti-fibrotic drugs used for patients with …
[PDF][PDF] Telomerase-positive stem cells as a potential treatment for idiopathic pulmonary fibrosis
HE Young, MO Speight, SE Williams… - Stem Cells Regen …, 2020 - researchgate.net
Idiopathic pulmonary fibrosis (IPF) belongs to a large collection of more than 200 lung
diseases known as interstitial lung diseases (ILD). While the cause of IPF is unknown, it has …
diseases known as interstitial lung diseases (ILD). While the cause of IPF is unknown, it has …
Association between weight loss and mortality in idiopathic pulmonary fibrosis
A Kalininskiy, AR Rackow, D Nagel, D Croft… - Respiratory …, 2022 - Springer
Rationale Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung
disease that has no cure. Many current research efforts center on diagnostic and therapeutic …
disease that has no cure. Many current research efforts center on diagnostic and therapeutic …
Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis
Background The antifibrotic drugs nintedanib and pirfenidone reduce disease progression
in idiopathic pulmonary fibrosis (IPF) and have also shown to improve survival. Switching …
in idiopathic pulmonary fibrosis (IPF) and have also shown to improve survival. Switching …